Patents Examined by Bruce R. Campell
  • Patent number: RE47439
    Abstract: The invention relates to an improved method for making agarose coated, agarose beads which contain cells. The method which is preferably automated, involves placing manufactured beads in a sample of mineral oil at a temperature gradient, such that the temperature drops as the bead moves through the oil. Preferably, a “trumpet tool” and a “straw tool” are employed in the method.
    Type: Grant
    Filed: August 2, 2016
    Date of Patent: June 18, 2019
    Assignee: THE ROGOSIN INSTITUTE
    Inventors: Lawrence Gazda, Melissa Laramore, Timothy Hamilton, Barry Smith
  • Patent number: RE47471
    Abstract: Heat-stable oligomeric recombinant polypeptides, presenting at least one antigenic epitope of the pre-fusion Respiratory Syncytial Virus (RSV) F protein, comprising the RSV F protein ectodomain, functionally deleted in the HRB region, transmembrane and cytoplasmic domains replaced with a heterologous trimerization domain, and absent two functional multibasic furin cleavage sites, are useful as antigenic components in immunogenic compositions useful in methods of inducing an immune response and vaccinate against RSV infections.
    Type: Grant
    Filed: March 26, 2016
    Date of Patent: July 2, 2019
    Assignee: Mucosis B.V.
    Inventors: Cornelis Alexander Maria de Haan, Petrus Josephus Marie Rottier, Bert Jan Haijema
  • Patent number: RE47528
    Abstract: We have identified by molecular cloning a protease which originates from the larvae of Lucilia sericata and which was termed debrilase due to its activities useful for debridement of wounds.
    Type: Grant
    Filed: January 25, 2018
    Date of Patent: July 23, 2019
    Assignee: B.R.A.I.N. BIOTECHNOLOGY RESEARCH AND INFORMATION NETWORK AG
    Inventors: Frank Niehaus, Jürgen Eck, Renate Schulze, Michael Krohn
  • Patent number: RE47666
    Abstract: Herbicide combinations comprising an effective amount of components (A) and (B), where component (A) is/are one or more herbicides of the formula (I) or salts thereof, in which R1 is H or a group of the formula CZ1Z2Z3, where Z1, Z2 and Z3 are as defined in claim 1, R2 and R3 are each H, alkyl, haloalkyl, alkenyl, haloalkenyl, alkynyl, haloalkynyl having in each case up to 4 carbon atoms or acyl, R4 is H, (C1-C6)-alkyl or (C1-C6)-alkoxy; R5, R6, R7 and R8 are each H, (C1-C4)-alkyl, (C1-C3)-haloalkyl, halogen, (C1-C3)-alkoxy, (C1-C3)-haloalkoxy or cyano; A is CH2 or O or a direct bond, and the component (B) is one or more herbicides from the group of compounds consisting of (B1) thiencarbazone, tembotrione, SYN-523, pyroxsulam, penoxsulam, SYN-449, (B2) pyrasulfotole, trifloxysulfuron, saflufenacil, aminopyralid, ethofumesate, aminocyclopyrachlor and (B3) pyroxasulfone (KIH-485) are suitable for controlling harmful plants or for regulating the growth of plants.
    Type: Grant
    Filed: March 29, 2016
    Date of Patent: October 29, 2019
    Assignee: BAYER CROPSCIENCE AKTIENGESELLSCHAFT
    Inventors: Erwin Hacker, Martin Hess, Martin Jeffrey Hills, Georg Bonfig-Picard, Thomas Auler
  • Patent number: RE47838
    Abstract: Disclosed are methods of treating and/or inhibiting a viral infection in a subject. The methods include administering a therapeutically effective amount of heparin-binding peptide. Also disclosed herein are methods for blocking viral binding to a cell. Further disclosed are anti-viral compositions for administration to a subject infected with a virus. Administration of the anti-viral composition inhibits viral infection of the subject.
    Type: Grant
    Filed: January 30, 2018
    Date of Patent: February 4, 2020
    Assignee: UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION
    Inventors: Jonathan S. Wall, Timothy E. Sparer, Stephen J. Kennel
  • Patent number: RE47873
    Abstract: Embolic compositions comprising macromers having a backbone comprising a polymeric backbone comprising units with a 1,2-diol or 1,3-diol structure, such as polyvinyl alcohol, and pendant chains bearing crosslinkable groups and, optionally, other modifiers. When crosslinked, the macromers form hydrogels having many properties advantageous for use as embolic agents to block and fill lumens and spaces. The embolic compositions can be used as liquid embolic agents and crosslinked in situ or as preformed embolic articles, such as microspheres.
    Type: Grant
    Filed: March 16, 2015
    Date of Patent: February 25, 2020
    Assignee: BIOCOMPATIBLES UK LIMITED
    Inventors: Dennis W. Goupil, Hassan Chaouk, Troy Holland, Bruktawit T. Asfaw, Stephen D. Goodrich, Lucas Latini
  • Patent number: RE47885
    Abstract: Described herein are cannabidiol prodrugs used in pharmaceutical compositions as well as microneedle drug delivery systems comprising a pharmaceutical compositions comprising pharmaceutically active agents (e.g., cannabidiol and prodrugs of cannabidiol) and microneedle arrays suitable for local and systemic delivery of the active agent to a mammal. Also described herein are methods of using a microneedle transdermal or topical drug delivery systems comprising pharmaceutical compositions, comprising cannabidiol and prodrugs of cannabidiol, and microneedle arrays in the treatment disease, including pancreatitis and pancreatic cancer.
    Type: Grant
    Filed: December 13, 2018
    Date of Patent: March 3, 2020
    Assignee: Zynerba Pharmaceuticals, Inc.
    Inventors: Audra Lynn Strinchcomb, Stan Lee Banks, Miroslaw Jerzy Golinski, Jeffrey Lynn Howard, Dana Carmel Hammel
  • Patent number: RE47972
    Abstract: The invention relates to Inter-alpha inhibitor proteins (I?Ip). The invention further relates to processes for purification of I?Ip compositions and their use for treatment of human diseases such as sepsis and septic shock, rheumatoid arthritis, cancer and infectious diseases.
    Type: Grant
    Filed: April 26, 2013
    Date of Patent: May 5, 2020
    Assignee: ProThera Biologics, Inc.
    Inventors: Yow-Pin Lim, Djuro Josic, Douglas C. Hixson
  • Patent number: RE47983
    Abstract: Provided herein are compositions and methods for identifying or quantitating one or more analytes in sample. The composition can comprise an affinity molecule reversibly conjugated to a label moiety via a double-stranded nucleic acid linker or via an adaptor molecule. The affinity molecule and the label moiety can be linked to different strands of the double-stranded nucleic acid linker. Compositions can be used in any biological assays for detection, identification and/or quantification of target molecules or analytes, including multiplex staining for molecular profiling of individual cells or cellular populations. For example, the compositions can be adapted for use in immunofluorescence, fluorescence in situ hybridization, immunohistochemistry, western blot, and the like.
    Type: Grant
    Filed: June 28, 2018
    Date of Patent: May 12, 2020
    Assignee: University of Washington through its Center for Commercialization
    Inventors: Xiaohu Gao, Pavel Zrazhevskiy
  • Patent number: RE48240
    Abstract: The disclosure is related generally to methods for testing mammary fluid (including milk) to establish or confirm the identity of the donor of the mammary fluid. Such methods are useful in the milk-bank business to improve safety.
    Type: Grant
    Filed: September 10, 2018
    Date of Patent: October 6, 2020
    Assignee: Prolacta Bioscience, Inc.
    Inventors: Elena M. Medo, Martin L. Lee, David J. Rechtman
  • Patent number: RE48254
    Abstract: The present invention is directed to lentil plants having increased resistance to an imidaizolinone herbicide. One such plant described herein is the RH44 lentil variety. The present invention also includes seeds produced by these lentil plants and methods of controlling weeds in the vicinity of these lentil plants.
    Type: Grant
    Filed: November 24, 2014
    Date of Patent: October 13, 2020
    Assignee: University of Saskatchewan
    Inventors: Al E Slinkard, Albert Vandenberg, Frederick A. Holm
  • Patent number: RE48267
    Abstract: The present disclosure provides variants of C-type natriuretic peptide (CNP), pharmaceutical compositions comprising CNP variants, and methods of making CNP variants. The CNP variants are useful as therapeutic agents for the treatment of diseases responsive to CNP, including but not limited to bone-related disorders, such as skeletal dysplasias (e.g., achondroplasia), and vascular smooth muscle disorders (e.g., restenosis and arteriosclerosis).
    Type: Grant
    Filed: July 11, 2017
    Date of Patent: October 20, 2020
    Assignee: BioMarin Pharmaceutical Inc.
    Inventors: Daniel J. Wendt, Shinong Long, Sianna Castillo, Christopher P. Price, Mika Aoyagi-Scharber, Michel Claude Vellard, Augustus O. Okhamafe
  • Patent number: RE48370
    Abstract: The present invention provides a method of measuring the levels of BCMA in a biological sample, specifically upon the B cell surface. The diagnostic assays are useful in predicting an individual's likelihood of developing or currently suffering from an autoimmune disease, such as SLE, and for methods for treating an individual clinically diagnosed with an autoimmune disease. This diagnostic test serves to predict a patient's likelihood to respond to a specific drug treatment, in particular treatment with BLyS antagonists, either singly or in combination with other immune suppressive drugs.
    Type: Grant
    Filed: October 4, 2018
    Date of Patent: December 29, 2020
    Assignees: ZYMOGENETICS, INC., UNIVERSITY OF WASHINGTON
    Inventors: Stacey R. Dillon, Jane A. Gross, Keith B. Elkon
  • Patent number: RE48445
    Abstract: Gas permeable devices and methods are disclosed for cell culture, including cell culture devices and methods that contain medium at heights, and certain gas permeable surface area to medium volume ratios. These devices and methods allow improvements in cell culture efficiency and scale up efficiency.
    Type: Grant
    Filed: June 12, 2018
    Date of Patent: February 23, 2021
    Assignee: Wilson Wolf Manufacturing
    Inventors: John R. Wilson, Douglas A. Page, Daniel Welch, Alison Robeck
  • Patent number: RE48461
    Abstract: Certain embodiments are directed to compounds and compositions targeted to human androgen receptor (AR) for inhibiting androgen receptor levels in a cell, which can be useful for methods of treating cancer and inhibiting cancer cell growth or proliferation.
    Type: Grant
    Filed: February 13, 2019
    Date of Patent: March 9, 2021
    Assignee: lonis Pharmaceuticals, Inc.
    Inventors: Robert A. Macleod, Youngsoo Kim, Tianyuan Zhou, Susan M. Freier, Punit Seth, Eric Swayze, Brett Monia
  • Patent number: RE48522
    Abstract: MHC Class I-restricted peptides derived from the tumor associated antigen, survivin, which peptides are capable of binding to Class I HLA molecules at a high affinity, capable of eliciting INF-?-producing cells in a PBL population of a cancer patient and capable of in situ detection of cytotoxic T cells in a tumor tissue, therapeutic and diagnostic composition comprising the peptide and uses thereof.
    Type: Grant
    Filed: July 19, 2018
    Date of Patent: April 20, 2021
    Assignee: SURVAC APS
    Inventors: Eivind Per Thor Straten, Mads Hald Andersen
  • Patent number: RE48608
    Abstract: The present invention provides methods to determine whether a patient with a lysosomal storage disorder will benefit from treatment with a specific pharmacological chaperone. The present invention exemplifies an in vitro method for determining ?-galactosidase A responsiveness to a pharmacological chaperone such as 1-deoxygalactonojirimycin in a cell line expressing a mutant from of ?-galactosidase A. The invention also provides a method for diagnosing Fabry disease in patients suspected of having Fabry disease.
    Type: Grant
    Filed: December 17, 2018
    Date of Patent: June 29, 2021
    Assignee: Amicus Therapeutics, Inc.
    Inventors: Elfrida Benjamin, Hung V. Do, John Flanagan, Xiaoyang Wu, Brandon Wustman
  • Patent number: RE48636
    Abstract: The present invention relates to decoy peptide or polypeptide consisting of a peptide sequence represented by the following Formula I: X1-Ala-X2—X3-Ile-Glu-X4 (I). It is noteworthy that the decoy peptide or polypeptide of the present invention significantly elevates phosphorylation levels of PLB by inhibiting PP1-mediated dephosphorylation. In addition, the decoy peptide or polypeptide provides cardio-protective effects by restoring of SERCA2a activity and inotropic effect of enhancing myocardial contractility. The present invention will contribute greatly to the prevention or treatment of diseases associated with PLB.
    Type: Grant
    Filed: October 24, 2019
    Date of Patent: July 13, 2021
    Assignee: BETHPHAGEN INC.
    Inventors: Woo Jin Park, Jae Gyun Oh
  • Patent number: RE48665
    Abstract: Method, composition, kit and system for isolating amplifiable nucleic acid from specimens preserved in a liquid-based cytology preservative that contains formaldehyde. The technique relies on the use of 2-imidazolidone and a protease enzyme, such as proteinase K, at elevated temperatures. Advantageously, RNA can be isolated and used as a template in nucleic acid amplification reactions.
    Type: Grant
    Filed: August 22, 2019
    Date of Patent: August 3, 2021
    Assignee: GEN-PROBE INCORPORATED
    Inventors: Deborah C. Jensen, Brett W. Kirkconnell, Timothy J. Wilson
  • Patent number: RE48732
    Abstract: Methods for selecting tag-oligonucleotide sequences for use in an in vitro nucleic acid assay. The selected tag sequences are useful for nucleic acid assay wherein interference between the nucleic acid sequences is the assay is to be controlled. Selected tag sequences are incorporated into nucleic acid assay to improve the performance of and/or minimize any interference between nucleic acids in the assay compared to untagged assays.
    Type: Grant
    Filed: July 19, 2018
    Date of Patent: September 14, 2021
    Assignee: GEN-PROBE INCORPORATED
    Inventors: Norman C. Nelson, Jijumon Chelliserry